Abstract: A system configured to create a self-contained negative pressure environment (SCONE) to remove airborne particulates emitted from a patient. The system prevents exposure to pathogenic biological airborne particulates during triage, transportation, and treatment, including aerosol generating procedures (AGPs) and end of life care. This system is directed to a collapsible device having a flexible cover covering two support members, with openings in the flexible cover such that medical professionals can reach in and operate within. The present invention is further adaptable to patients and operating environments of various sizes.

Abstract: A system configured to create a self-contained negative pressure environment (SCONE) to remove airborne particulates emitted from a patient. The system prevents exposure to pathogenic biological airborne particulates during triage, transportation, and treatment, including aerosol generating procedures (AGPs) and end of life care. This system is directed to a collapsible device having a flexible cover covering two support members, with openings in the flexible cover such that medical professionals can reach in and operate within. The present invention is further adaptable to patients and operating environments of various sizes.

Abstract: A system directed to providing a self-contained negative pressure environment (SCONE) to remove airborne particulates emitted from a patient. The system prevents exposure to pathogenic biological airborne particulates during triage, transportation, and treatment, including aerosol generating procedures (AGPs) and end of life care. This system is directed to a collapsible device having a flexible cover covering two support members, with openings in the flexible cover such that medical professionals can reach in and operate within. The present invention is further adaptable to patients and operating environments of various sizes.

Abstract: Novel methods and imaging agents for functional imaging of lymph structures are disclosed herein. Embodiments of the methods utilize highly sensitive optical imaging and fluorescent spectroscopy techniques to track or monitor packets of organic dye flowing in one or more lymphatic structures. The packets of organic dye may be tracked to provide quantitative information regarding lymph propulsion and function. In particular, lymph flow velocity and pulse frequency may be determined using the disclosed methods.

Abstract: Novel methods and imaging agents for functional imaging of lymph structures are disclosed herein. Embodiments of the methods utilize highly sensitive optical imaging and fluorescent spectroscopy techniques to track or monitor packets of organic dye flowing in one or more lymphatic structures. The packets of organic dye may be tracked to provide quantitative information regarding lymph propulsion and function. In particular, lymph flow velocity and pulse frequency may be determined using the disclosed methods.

Abstract: Novel methods and imaging agents for functional imaging of lymph structures are disclosed herein. Embodiments of the methods utilize highly sensitive optical imaging and fluorescent spectroscopy techniques to track or monitor packets of organic dye flowing in one or more lymphatic structures. The packets of organic dye may be tracked to provide quantitative information regarding lymph propulsion and function. In particular, lymph flow velocity and pulse frequency may be determined using the disclosed methods.

Abstract: Novel methods and imaging agents for functional imaging of lymph structures are disclosed herein. Embodiments of the methods utilize highly sensitive optical imaging and fluorescent spectroscopy techniques to track or monitor packets of organic dye flowing in one or more lymphatic structures. The packets of organic dye may be tracked to provide quantitative information regarding lymph propulsion and function. In particular, lymph flow velocity and pulse frequency may be determined using the disclosed methods.

Abstract: Novel methods and imaging agents for functional imaging of lymph structures are disclosed herein. Embodiments of the methods utilize highly sensitive optical imaging and fluorescent spectroscopy techniques to track or monitor packets of organic dye flowing in one or more lymphatic structures. The packets of organic dye may be tracked to provide quantitative information regarding lymph propulsion and function. In particular, lymph flow velocity and pulse frequency may be determined using the disclosed methods.

Abstract: Methods and imaging agents for imaging epithelial cancer cells in the lymphatic system are disclosed herein. In an embodiment, an imaging agent for imaging cancer cells in a lymphatic system comprises a fluorescent dye conjugated to one or more antibodies. The antibodies are capable of specific binding to an epithelial cell adhesion molecule (Ep-CAM). In addition, embodiments of the imaging agent may be administered to the lymphatic system where the disclosed imaging agents may bind to an epithelial cell adhesion molecule. The bound imaging agents may be excited with excitation light to image cancer cells in the lymphatic system.